Octreotide in Palliative Treatment of Hepatic Metastases: Is it Effective for Clinical Stabilization?

Published on Thursday, 16 January 2014


K Pistevou-Gombaki et al. presented their positive experience from the palliative use of octreotide LAR in hepatic metastases from non-neuroendocrine tumors. On the other hand, there are several negative prospective studies of octreotide efficacy in liver metastases and this policy is not accepted from al oncologists. According to this literature controversy and in continuation to the above-mentioned studies, we would like to report our recent experience from the efficient use of octreotide LAR in seven patients with symptomatic liver metastases from non-neuroendocrine tumors and in one female (80-years-old) with duodenal carcinoid.


About this Letter to the Editor.

See also:

- Official Web Site: The Di Bella Method;

- Somatostatin in oncology, the overlooked evidences - In vitro, review and in vivo publications;

- The Di Bella Method (A Fixed Part - Somatostatin, Octreotide, Sandostatin LAR, analogues and/or derivatives);

- The Di Bella Method (A Fixed Part - Cyclophosphamide 50mg tablets and/or Hydroxyurea 500mg tablets, one or two per day);

- Pancreatic Adenocarcinoma: clinical records on 17 patients treated with Di Bella's Method;

- The Di Bella Method Increases by the 30% the survival rate for Pancreas tumors and for this reason should be proposed as first line therapy for this type of cancer.